{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:32:56Z","timestamp":1787106776555,"version":"build-2736575974"},"reference-count":163,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009367","name":"Mansoura University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009367","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pediatric disorders consist of genetic, hematologic, neurologic, autoimmune, and inflammatory diseases. These conditions impose long-term health challenges on children, despite many advancements with conventional medicine. Although conventional treatments increase life expectancy and provide better disease control, many present challenges such as toxicity, insufficient control of the disease, and adverse effects on normal growth, development, and quality of life. Many researchers have shown increased interest in using stem cell therapies as an alternative to current medications to allow for complete, sustainable repair of damaged tissues and modification of disease processes (i.e., using stem cells to regenerate tissue or change the way in which a disease occurs). This paper will provide the current information on stem cells used in the treatment of children and the many different types of stem cells, including: hematopoietic stem cells (and their derivatives), mesenchymal stem cells (and their derivatives), induced pluripotent stem cells, embryonic stem cells, tissue-specific progenitor cells, extracellular vesicles, and bioengineered products. This paper will also discuss what is known about the stem cells listed as well as their methods of action, where they might currently be better utilized, and future uses of these cells in children for a variety of types of pediatric diseases. Because each stem cell type listed has very different scientific background and clinical evidence, there is much variability in the amount of scientific evidence available to support stem cell therapies. For example, hematopoietic stem cell transplantation (HSCT) has over 50 years of clinical experience; thus, there are many studies defining the clinical efficacy and long-term outcomes associated with HSCT. Conversely, while there are many published studies supporting the use of mesenchymal stem cells (MSCs), extracellular vesicles (EVs), gene-edited cells, organoids, and many induced pluripotent stem cell-derived therapies, more evidence (clinical and basic science) is still needed to fully establish efficacy for the use of these various stem cells in children with pediatric diseases. In addition to needing more clinical evidence, stem cell-based therapies face many important challenges to the advancement of these therapies, including (but not limited to) long-term safety assessments, manufacturing standardization, regulatory oversight, ethical concerns, and equitable access to advanced therapies. Addressing these challenges will be important for future advances in the use of regenerative medicine in pediatric patients which will also require the rigorous evaluation of new stem cell therapies, the continued improvement of translational mechanisms, and the ongoing incorporation of new techniques (e.g., genome editing, organoid modeling, EV therapeutics, bioengineering, and artificial intelligence) to advance regenerative medicine and demonstrate its value through safe and reproducible clinical trial results.<\/jats:p>","DOI":"10.1186\/s13287-026-05204-0","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T12:53:13Z","timestamp":1786798393000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stem cell\u2013based therapies in pediatric disorders: translational advances, unresolved challenges, and future horizons"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0069-4212","authenticated-orcid":false,"given":"Hany E.","family":"Marei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,15]]},"reference":[{"key":"5204_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/978-3-031-44080-9_37","volume-title":"The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies","author":"JA Maertens","year":"2024","unstructured":"Maertens JA. Invasive Fungal Diseases. In: The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies. 2024. p. 321\u20139."},{"key":"5204_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14103494","volume":"14","author":"H AlHumaidan","year":"2025","unstructured":"AlHumaidan H, et al. Position paper on the management of sickle cell disease in Saudi Arabia: understanding disease landscape, identifying challenges, and exploring opportunities in transfusion therapies. J Clin Med. 2025;14:3494.","journal-title":"J Clin Med"},{"key":"5204_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2023.1343104","volume":"10","author":"T Feit","year":"2024","unstructured":"Feit T, Beals E, Dandekar S, Kadan-Lottick N, Joffe L. Nutritional assessment and dietary intervention among survivors of childhood cancer: current landscape and a look to the future. Front Nutr. 2024;10:1343104.","journal-title":"Front Nutr"},{"key":"5204_CR4","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1080\/14737140.2024.2411255","volume":"24","author":"B Phillips","year":"2024","unstructured":"Phillips B, Morgan J, Walker R, Heggie C, Ali S. Interventions to reduce the risk of side-effects of cancer treatments in childhood. Expert Rev Anticancer Ther. 2024;24:1117\u201329.","journal-title":"Expert Rev Anticancer Ther"},{"key":"5204_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/stcltm\/szae102","volume":"14","author":"C Maltais-Bilodeau","year":"2025","unstructured":"Maltais-Bilodeau C, et al. Cell-based therapies in preclinical models of necrotizing enterocolitis: a systematic review and meta-analysis. Stem Cells Transl Med. 2025;14:szae102.","journal-title":"Stem Cells Transl Med"},{"key":"5204_CR6","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.3390\/biomedicines13071527","volume":"13","author":"B Amoozgar","year":"2025","unstructured":"Amoozgar B, et al. JAK2 Inhibitors and Emerging Therapies in Graft-Versus-Host Disease: Current Perspectives and Future Directions. Biomedicines. 2025;13:1527.","journal-title":"Biomedicines"},{"key":"5204_CR7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.44865","author":"NC Peddi","year":"2023","unstructured":"Peddi NC, Vuppalapati S, Sreenivasulu H, kumar Muppalla S, Pulliahgaru AR. Guardians of immunity: advances in primary immunodeficiency disorders and management. Cureus. 2023. https:\/\/doi.org\/10.7759\/cureus.44865.","journal-title":"Cureus"},{"key":"5204_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.774853","volume":"9","author":"M Gabriel","year":"2021","unstructured":"Gabriel M, et al. A review of acute and long-term neurological complications following haematopoietic stem cell transplant for paediatric acute lymphoblastic leukaemia. Front Pediatr. 2021;9:774853.","journal-title":"Front Pediatr"},{"key":"5204_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/2052-8426-2-31","volume":"2","author":"S Casarosa","year":"2014","unstructured":"Casarosa S, Bozzi Y, Conti L. Neural stem cells: ready for therapeutic applications? Mol Cell Ther. 2014;2:31.","journal-title":"Mol Cell Ther"},{"key":"5204_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10173790","volume":"10","author":"M Algeri","year":"2021","unstructured":"Algeri M, Merli P, Locatelli F, Pagliara D. The role of allogeneic hematopoietic stem cell transplantation in pediatric leukemia. J Clin Med. 2021;10:3790.","journal-title":"J Clin Med"},{"key":"5204_CR11","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.1182\/bloodadvances.2022009646","volume":"7","author":"X Zhang","year":"2023","unstructured":"Zhang X, et al. Mesenchymal stromal cells ameliorate chronic GVHD by boosting thymic regeneration in a CCR9-dependent manner in mice. Blood Adv. 2023;7:5359\u201373.","journal-title":"Blood Adv"},{"key":"5204_CR12","doi-asserted-by":"publisher","first-page":"e581","DOI":"10.1097\/HS9.0000000000000581","volume":"5","author":"LM Braun","year":"2021","unstructured":"Braun LM, Zeiser R. Immunomodulatory Therapies for the Treatment of Graft-versus-host Disease. Hemasphere. 2021;5:e581.","journal-title":"Hemasphere"},{"key":"5204_CR13","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1210\/clinem\/dgae196","volume":"110","author":"SL-K Lee","year":"2025","unstructured":"Lee SL-K, et al. The late effects of hematopoietic stem cell transplants in pediatric patients: a 25-year review. J Clin Endocrinol Metabolism. 2025;110:e347\u201362.","journal-title":"J Clin Endocrinol Metabolism"},{"key":"5204_CR14","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1002\/stem.2417","volume":"34","author":"D Jiang","year":"2016","unstructured":"Jiang D, et al. Suppression of neutrophil-mediated tissue damage\u2014a novel skill of mesenchymal stem cells. Stem Cells. 2016;34:2393\u2013406.","journal-title":"Stem Cells"},{"key":"5204_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cells10020294","volume":"10","author":"K-X Wang","year":"2021","unstructured":"Wang K-X, et al. Mesenchymal stem cells for mitigating radiotherapy side effects. Cells. 2021;10:294.","journal-title":"Cells"},{"key":"5204_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.578984","volume":"8","author":"E Villamor-Martinez","year":"2020","unstructured":"Villamor-Martinez E, Hundscheid T, Kramer BW, Hooijmans CR, Villamor E. Stem cells as therapy for necrotizing enterocolitis: a systematic review and meta-analysis of preclinical studies. Front Pediatr. 2020;8:578984.","journal-title":"Front Pediatr"},{"key":"5204_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cells12151963","volume":"12","author":"K Das","year":"2023","unstructured":"Das K, et al. Beyond macromolecules: extracellular vesicles as regulators of inflammatory diseases. Cells. 2023;12:1963.","journal-title":"Cells"},{"key":"5204_CR18","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1172\/JCI90367","volume":"127","author":"KL Shaw","year":"2017","unstructured":"Shaw KL, et al. Clinical efficacy of gene-modified stem cells in adenosine deaminase\u2013deficient immunodeficiency. J Clin Invest. 2017;127:1689\u201399.","journal-title":"J Clin Invest"},{"key":"5204_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1162605","volume":"14","author":"M Slatter","year":"2023","unstructured":"Slatter M, Lum SH. Personalized hematopoietic stem cell transplantation for inborn errors of immunity. Front Immunol. 2023;14:1162605.","journal-title":"Front Immunol"},{"key":"5204_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2023.1343104","volume":"10","author":"T Feit","year":"2024","unstructured":"Feit T, Beals E, Dandekar S, Kadan-Lottick N, Joffe L. Nutritional assessment and dietary intervention among survivors of childhood cancer: current landscape and a look to the future. Front Nutr. 2024;10:1343104.","journal-title":"Front Nutr"},{"key":"5204_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1517\/14712598.5.2.153","volume":"5","author":"KK Jain","year":"2005","unstructured":"Jain KK. Ethical and regulatory aspects of embryonic stem cell research. Expert Opin Biol Ther. 2005;5:153\u201362.","journal-title":"Expert Opin Biol Ther"},{"key":"5204_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13287-025-04334-1","volume":"16","author":"HE Marei","year":"2025","unstructured":"Marei HE. Stem cell therapy: a revolutionary cure or a pandora\u2019s box. Stem Cell Res Ther. 2025;16:255.","journal-title":"Stem Cell Res Ther"},{"key":"5204_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13046-020-01584-0","volume":"39","author":"K Wuputra","year":"2020","unstructured":"Wuputra K, et al. Prevention of tumor risk associated with the reprogramming of human pluripotent stem cells. J Experimental Clin Cancer Res. 2020;39:100.","journal-title":"J Experimental Clin Cancer Res"},{"key":"5204_CR24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.4252\/wjsc.v8.i4.118","volume":"8","author":"P Spitalieri","year":"2016","unstructured":"Spitalieri P, Talarico VR, Murdocca M, Novelli G, Sangiuolo F. Human induced pluripotent stem cells for monogenic disease modelling and therapy. World J stem cells. 2016;8:118.","journal-title":"World J stem cells"},{"key":"5204_CR25","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861\u201372.","journal-title":"Cell"},{"key":"5204_CR26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nature10761","volume":"481","author":"DA Robinton","year":"2012","unstructured":"Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature. 2012;481:295\u2013305.","journal-title":"Nature"},{"key":"5204_CR27","doi-asserted-by":"crossref","unstructured":"Bas\u00edlio-Queir\u00f3s D, Rivi\u00e8re I, van der Stegen SJ, Lachmann N. iPSC-derived T cells and macrophages: Manufacturing and next-generation application approaches. Adv Drug Deliv Rev 2025;115713.","DOI":"10.1016\/j.addr.2025.115713"},{"key":"5204_CR28","doi-asserted-by":"publisher","first-page":"539","DOI":"10.5966\/sctm.2015-0427","volume":"6","author":"CR Nitkin","year":"2017","unstructured":"Nitkin CR, Bonfield TL. Concise review: mesenchymal stem cell therapy for pediatric disease: perspectives on success and potential improvements. Stem cells translational Med. 2017;6:539\u201365.","journal-title":"Stem cells translational Med"},{"key":"5204_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/stcltm\/szaf050","volume":"14","author":"S Hwang","year":"2025","unstructured":"Hwang S, et al. Extracellular vesicles from mesenchymal stromal cells: an emerging therapy for intractable neonatal disorders. Stem Cells Transl Med. 2025;14:szaf050.","journal-title":"Stem Cells Transl Med"},{"key":"5204_CR30","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.1007\/s12010-023-04752-y","volume":"196","author":"W Chen","year":"2024","unstructured":"Chen W, Ren Q, Zhou J, Liu W. Mesenchymal stem cell-induced neuroprotection in pediatric neurological diseases: Recent update of underlying mechanisms and clinical utility. Appl Biochem Biotechnol. 2024;196:5843\u201358.","journal-title":"Appl Biochem Biotechnol"},{"key":"5204_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-025-04550-9","volume":"16","author":"R Fatahi","year":"2025","unstructured":"Fatahi R, Heydarpour F, Motlagh SM, Mansouri K. Evaluation of stem\/stromal cell transplantation safety and efficacy in children diagnosed with cerebral palsy: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Ther. 2025;16:468.","journal-title":"Stem Cell Res Ther"},{"key":"5204_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/cbin.70042","author":"F Alizadeh","year":"2025","unstructured":"Alizadeh F, Yasrebinia S. Harnessing stem cells for pediatric respiratory diseases: potential and clinical translation. Cell Biol Int. 2025. https:\/\/doi.org\/10.1002\/cbin.70042.","journal-title":"Cell Biol Int"},{"key":"5204_CR33","volume":"12","author":"I Kostareva","year":"2025","unstructured":"Kostareva I, et al. Allogeneic hematopoietic stem cell transplantation for infant leukemia: a single-center case series and narrative review. Children (Basel). 2025;12:1418.","journal-title":"Children (Basel)"},{"key":"5204_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2025.1663600","volume":"13","author":"L Hiskey","year":"2025","unstructured":"Hiskey L, Hijano DR, Zakhour R. Revisiting cytomegalovirus in pediatric allogeneic hematopoietic stem cell transplant recipients: current strategies for prevention and management in the letermovir era. Front Pediatr. 2025;13:1663600.","journal-title":"Front Pediatr"},{"key":"5204_CR35","doi-asserted-by":"publisher","first-page":"6618","DOI":"10.1097\/MS9.0000000000003823","volume":"87","author":"EI Obeagu","year":"2025","unstructured":"Obeagu EI. Umbilical cord blood: a comprehensive review of protective and restorative properties in clinical applications\u2013a narrative review. Annals Med Surg. 2025;87:6618\u201325.","journal-title":"Annals Med Surg"},{"key":"5204_CR36","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1002\/jcp.25826","volume":"232","author":"HE Marei","year":"2017","unstructured":"Marei HE, et al. Nanotubes impregnated human olfactory bulb neural stem cells promote neuronal differentiation in Trimethyltin-induced neurodegeneration rat model. J Cell Physiol. 2017;232:3586\u201397.","journal-title":"J Cell Physiol"},{"key":"5204_CR37","unstructured":"Marei H. Effects of estrogen on Survival and Neuronal Differentiation of adult human olfactory bulb neural stem Cells Transplanted into Spinal Cord Injured Rats. 2019."},{"key":"5204_CR38","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1002\/jcp.26008","volume":"233","author":"HE Marei","year":"2018","unstructured":"Marei HE, et al. Differentiation of human olfactory bulb-derived neural stem cells toward oligodendrocyte. J Cell Physiol. 2018;233:1321\u20139.","journal-title":"J Cell Physiol"},{"key":"5204_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028420","volume":"6","author":"HE Marei","year":"2011","unstructured":"Marei HE, et al. Gene expression profiling of embryonic human neural stem cells and dopaminergic neurons from adult human substantia nigra. PLoS One. 2011;6:e28420.","journal-title":"PLoS One"},{"key":"5204_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00034","volume":"9","author":"HE Marei","year":"2018","unstructured":"Marei HE, et al. Potential of stem cell-based therapy for ischemic stroke. Front Neurol. 2018;9:271733.","journal-title":"Front Neurol"},{"key":"5204_CR41","doi-asserted-by":"publisher","first-page":"891","DOI":"10.4252\/wjsc.v11.i10.891","volume":"11","author":"S Eggenberger","year":"2019","unstructured":"Eggenberger S, et al. Stem cell treatment and cerebral palsy: Systemic review and meta-analysis. World J stem cells. 2019;11:891.","journal-title":"World J stem cells"},{"key":"5204_CR42","doi-asserted-by":"publisher","first-page":"539","DOI":"10.5966\/sctm.2015-0427","volume":"6","author":"CR Nitkin","year":"2017","unstructured":"Nitkin CR, Bonfield TL. Concise review: mesenchymal stem cell therapy for pediatric disease: perspectives on success and potential improvements. Stem cells translational Med. 2017;6:539\u201365.","journal-title":"Stem cells translational Med"},{"key":"5204_CR43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1172\/JCI40543","volume":"120","author":"O Lindvall","year":"2010","unstructured":"Lindvall O, Kokaia Z. Stem cells in human neurodegenerative disorders\u2014time for clinical translation? J Clin Investig. 2010;120:29\u201340.","journal-title":"J Clin Investig"},{"key":"5204_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.stem.2015.06.007","volume":"17","author":"A Trounson","year":"2015","unstructured":"Trounson A, McDonald C. Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell. 2015;17:11\u201322.","journal-title":"Cell Stem Cell"},{"key":"5204_CR45","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nrm.2016.10","volume":"17","author":"A Trounson","year":"2016","unstructured":"Trounson A, DeWitt ND. Pluripotent stem cells progressing to the clinic. Nat Rev Mol Cell Biol. 2016;17:194\u2013200.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"5204_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.567210","volume":"11","author":"O Ringd\u00e9n","year":"2020","unstructured":"Ringd\u00e9n O, Gustafsson B, Sadeghi B. Mesenchymal stromal cells in pediatric hematopoietic cell transplantation a review and a pilot study in children treated with decidua stromal cells for acute graft-versus-host disease. Front Immunol. 2020;11:567210.","journal-title":"Front Immunol"},{"key":"5204_CR47","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1182\/blood-2002-02-0564","volume":"100","author":"O Kollet","year":"2002","unstructured":"Kollet O, et al. Human CD34\u2009+\u2009CXCR4\u2212 sorted cells harbor intracellular CXCR4, which can be functionally expressed and provide NOD\/SCID repopulation. Blood. 2002;100:2778\u201386.","journal-title":"Blood"},{"key":"5204_CR48","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nature11926","volume":"495","author":"A Greenbaum","year":"2013","unstructured":"Greenbaum A, et al. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature. 2013;495:227\u201330.","journal-title":"Nature"},{"key":"5204_CR49","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1089\/scd.2020.0191","volume":"30","author":"M D\u00f6ring","year":"2021","unstructured":"D\u00f6ring M, et al. Long-term follow-up after the application of mesenchymal stromal cells in children and adolescents with steroid-refractory graft-versus-host disease. Stem Cells Dev. 2021;30:234\u201346.","journal-title":"Stem Cells Dev"},{"key":"5204_CR50","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1089\/scd.2021.0352","volume":"31","author":"KM Cabanillas Stanchi","year":"2022","unstructured":"Cabanillas Stanchi KM, et al. Hematopoietic stem cell transplantation with mesenchymal stromal cells in children with metachromatic leukodystrophy. Stem Cells Dev. 2022;31:163\u201375.","journal-title":"Stem Cells Dev"},{"key":"5204_CR51","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1007\/s00018-020-03454-6","volume":"77","author":"X-L Fan","year":"2020","unstructured":"Fan X-L, Zhang Y, Li X, Fu Q-L. Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy. Cell Mol Life Sci. 2020;77:2771\u201394.","journal-title":"Cell Mol Life Sci"},{"key":"5204_CR52","doi-asserted-by":"publisher","first-page":"5979","DOI":"10.7150\/thno.40122","volume":"10","author":"S Varderidou-Minasian","year":"2020","unstructured":"Varderidou-Minasian S, Lorenowicz MJ. Mesenchymal stromal\/stem cell-derived extracellular vesicles in tissue repair: challenges and opportunities. Theranostics. 2020;10:5979.","journal-title":"Theranostics"},{"key":"5204_CR53","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12969-021-00575-5","volume":"19","author":"SC Wong","year":"2021","unstructured":"Wong SC, Medrano LC, Hoftman AD, Jones OY, McCurdy DK. Uncharted waters: mesenchymal stem cell treatment for pediatric refractory rheumatic diseases; a single center case series. Pediatr Rheumatol. 2021;19:87.","journal-title":"Pediatr Rheumatol"},{"key":"5204_CR54","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1515\/cipms-2017-0022","volume":"30","author":"E Wawryk-Gawda","year":"2017","unstructured":"Wawryk-Gawda E, Wojcik B. Application of mesenchymal stem cells in paediatrics. Curr Issues Pharm Med Sci. 2017;30:123\u20138.","journal-title":"Curr Issues Pharm Med Sci"},{"key":"5204_CR55","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/stmcls\/sxac062","volume":"40","author":"E Delavogia","year":"2022","unstructured":"Delavogia E, et al. Mesenchymal stromal\/stem cell extracellular vesicles and perinatal injury: One formula for many diseases. Stem Cells. 2022;40:991\u20131007.","journal-title":"Stem Cells"},{"key":"5204_CR56","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1186\/s13287-025-04708-5","volume":"16","author":"W-L Hwang","year":"2025","unstructured":"Hwang W-L, et al. Harnessing engineered mesenchymal stem cell-derived extracellular vesicles for innovative cancer treatments. Stem Cell Res Ther. 2025;16:648.","journal-title":"Stem Cell Res Ther"},{"key":"5204_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1595897","volume":"13","author":"J Shu","year":"2025","unstructured":"Shu J, et al. CRISPR\/Cas-edited iPSCs and mesenchymal stem cells: a concise review of their potential in thalassemia therapy. Front Cell Dev Biol. 2025;13:1595897.","journal-title":"Front Cell Dev Biol"},{"key":"5204_CR58","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1126\/science.287.5457.1433","volume":"287","author":"FH Gage","year":"2000","unstructured":"Gage FH. Mammalian neural stem cells. Science. 2000;287:1433\u20138.","journal-title":"Science"},{"key":"5204_CR59","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s13287-022-02973-2","volume":"13","author":"Y Ji","year":"2022","unstructured":"Ji Y, et al. Clinical trials of stem cell-based therapies for pediatric diseases: a comprehensive analysis of trials registered on ClinicalTrials. gov and the ICTRP portal site. Stem Cell Res Ther. 2022;13:307.","journal-title":"Stem Cell Res Ther"},{"key":"5204_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.567210","volume":"11","author":"O Ringd\u00e9n","year":"2020","unstructured":"Ringd\u00e9n O, Gustafsson B, Sadeghi B. Mesenchymal stromal cells in pediatric hematopoietic cell transplantation a review and a pilot study in children treated with decidua stromal cells for acute graft-versus-host disease. Front Immunol. 2020;11:567210.","journal-title":"Front Immunol"},{"key":"5204_CR61","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1089\/ten.tea.2020.0088","volume":"27","author":"D Iacobazzi","year":"2021","unstructured":"Iacobazzi D, et al. Wharton\u2019s jelly-mesenchymal stem cell-engineered conduit for pediatric translation in heart defect. Tissue Eng Part A. 2021;27:201\u201313.","journal-title":"Tissue Eng Part A"},{"key":"5204_CR62","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13287-015-0081-6","volume":"6","author":"Y-W Lan","year":"2015","unstructured":"Lan Y-W, et al. Hypoxia-preconditioned mesenchymal stem cells attenuate bleomycin-induced pulmonary fibrosis. Stem Cell Res Ther. 2015;6:97.","journal-title":"Stem Cell Res Ther"},{"key":"5204_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/cells14030149","volume":"14","author":"SEM Abbas","year":"2025","unstructured":"Abbas SEM, Maged G, Wang H, Lotfy A. Mesenchymal stem\/stromal cells microencapsulation for cell therapy. Cells. 2025;14:149.","journal-title":"Cells"},{"key":"5204_CR64","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s13287-022-02973-2","volume":"13","author":"Y Ji","year":"2022","unstructured":"Ji Y, et al. Clinical trials of stem cell-based therapies for pediatric diseases: a comprehensive analysis of trials registered on ClinicalTrials. gov and the ICTRP portal site. Stem Cell Res Ther. 2022;13:307.","journal-title":"Stem Cell Res Ther"},{"key":"5204_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53613-7","volume":"15","author":"M Luciani","year":"2024","unstructured":"Luciani M, et al. Human iPSC-derived neural stem cells displaying radial glia signature exhibit long-term safety in mice. Nat Commun. 2024;15:9433.","journal-title":"Nat Commun"},{"key":"5204_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52400-8","volume":"15","author":"P Douvaras","year":"2024","unstructured":"Douvaras P, et al. Ready-to-use iPSC-derived microglia progenitors for the treatment of CNS disease in mouse models of neuropathic mucopolysaccharidoses. Nat Commun. 2024;15:8132.","journal-title":"Nat Commun"},{"key":"5204_CR67","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1089\/scd.2021.0352","volume":"31","author":"KM Cabanillas Stanchi","year":"2022","unstructured":"Cabanillas Stanchi KM, et al. Hematopoietic stem cell transplantation with mesenchymal stromal cells in children with metachromatic leukodystrophy. Stem Cells Dev. 2022;31:163\u201375.","journal-title":"Stem Cells Dev"},{"key":"5204_CR68","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12887-021-02562-x","volume":"21","author":"Y Lan","year":"2021","unstructured":"Lan Y, et al. Combination of umbilical cord mesenchymal stem cells and standard immunosuppressive regimen for pediatric patients with severe aplastic anemia. BMC Pediatr. 2021;21:102.","journal-title":"BMC Pediatr"},{"key":"5204_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1561174","volume":"16","author":"K Rassek","year":"2025","unstructured":"Rassek K, et al. New player in CAR-T manufacture field: comparison of umbilical cord to peripheral blood strategies. Front Immunol. 2025;16:1561174.","journal-title":"Front Immunol"},{"key":"5204_CR70","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.1007\/s12010-023-04752-y","volume":"196","author":"W Chen","year":"2024","unstructured":"Chen W, Ren Q, Zhou J, Liu W. Mesenchymal stem cell-induced neuroprotection in pediatric neurological diseases: Recent update of underlying mechanisms and clinical utility. Appl Biochem Biotechnol. 2024;196:5843\u201358.","journal-title":"Appl Biochem Biotechnol"},{"key":"5204_CR71","volume":"2013","author":"L Wang","year":"2013","unstructured":"Wang L, et al. Therapeutic potential of umbilical cord mesenchymal stromal cells transplantation for cerebral palsy: a case report. Case Rep Transplant. 2013;2013:146347.","journal-title":"Case Rep Transplant"},{"key":"5204_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-022-03153-y","volume":"13","author":"Y Xi","year":"2022","unstructured":"Xi Y, Yue G, Gao S, Ju R, Wang Y. Human umbilical cord blood mononuclear cells transplantation for perinatal brain injury. Stem Cell Res Ther. 2022;13:458.","journal-title":"Stem Cell Res Ther"},{"key":"5204_CR73","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/stcltm\/szad027","volume":"12","author":"CM Cotten","year":"2023","unstructured":"Cotten CM, et al. A pilot phase I trial of allogeneic umbilical cord tissue-derived mesenchymal stromal cells in neonates with hypoxic-ischemic encephalopathy. Stem Cells Transl Med. 2023;12:355\u201364.","journal-title":"Stem Cells Transl Med"},{"key":"5204_CR74","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/978-1-4939-3584-0_7","volume-title":"Mesenchymal Stem Cells: Methods and Protocols","author":"M Gnecchi","year":"2016","unstructured":"Gnecchi M, Danieli P, Malpasso G, Ciuffreda MC. Paracrine mechanisms of mesenchymal stem cells in tissue repair. In: Mesenchymal Stem Cells: Methods and Protocols. 2016. p. 123\u201346."},{"key":"5204_CR75","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/stmcls\/sxac062","volume":"40","author":"E Delavogia","year":"2022","unstructured":"Delavogia E, et al. Mesenchymal stromal\/stem cell extracellular vesicles and perinatal injury: One formula for many diseases. Stem Cells. 2022;40:991\u20131007.","journal-title":"Stem Cells"},{"key":"5204_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11080404","volume":"11","author":"AC Matei","year":"2019","unstructured":"Matei AC, Antounians L, Zani A. Extracellular vesicles as a potential therapy for neonatal conditions: state of the art and challenges in clinical translation. Pharmaceutics. 2019;11:404.","journal-title":"Pharmaceutics"},{"key":"5204_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-020-01764-x","volume":"11","author":"J Martinez","year":"2020","unstructured":"Martinez J, Zoretic S, Moreira A, Moreira A. Safety and efficacy of cell therapies in pediatric heart disease: a systematic review and meta-analysis. Stem Cell Res Ther. 2020;11:272.","journal-title":"Stem Cell Res Ther"},{"key":"5204_CR78","doi-asserted-by":"publisher","DOI":"10.1093\/stcltm\/szaf050","volume":"14","author":"S Hwang","year":"2025","unstructured":"Hwang S, et al. Extracellular vesicles from mesenchymal stromal cells: an emerging therapy for intractable neonatal disorders. Stem Cells Transl Med. 2025;14:szaf050.","journal-title":"Stem Cells Transl Med"},{"key":"5204_CR79","doi-asserted-by":"publisher","DOI":"10.4252\/wjsc.v17.i8.106086","volume":"17","author":"MS Choudhery","year":"2025","unstructured":"Choudhery MS, Arif T, Mahmood R. Applications of artificial intelligence in stem cell therapy. World J Stem Cells. 2025;17:106086.","journal-title":"World J Stem Cells"},{"key":"5204_CR80","doi-asserted-by":"publisher","DOI":"10.4252\/wjsc.v17.i8.106086","volume":"17","author":"MS Choudhery","year":"2025","unstructured":"Choudhery MS, Arif T, Mahmood R. Applications of artificial intelligence in stem cell therapy. World J Stem Cells. 2025;17:106086.","journal-title":"World J Stem Cells"},{"key":"5204_CR81","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1210\/er.2008-0031","volume":"30","author":"B Lo","year":"2009","unstructured":"Lo B, Parham L. Ethical issues in stem cell research. Endocr Rev. 2009;30:204\u201313.","journal-title":"Endocr Rev"},{"key":"5204_CR82","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1172\/JCI40435","volume":"120","author":"I Hyun","year":"2010","unstructured":"Hyun I. The bioethics of stem cell research and therapy. J Clin Invest. 2010;120:71\u20135.","journal-title":"J Clin Invest"},{"key":"5204_CR83","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.stem.2016.08.012","volume":"19","author":"M Abou-El-Enein","year":"2016","unstructured":"Abou-El-Enein M, Elsanhoury A, Reinke P. Overcoming challenges facing advanced therapies in the EU market. Cell Stem Cell. 2016;19:293\u20137.","journal-title":"Cell Stem Cell"},{"key":"5204_CR84","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12910-015-0069-x","volume":"16","author":"KR Matthews","year":"2015","unstructured":"Matthews KR, Iltis AS. Unproven stem cell\u2013based interventions and achieving a compromise policy among the multiple stakeholders. BMC Med Ethics. 2015;16:75.","journal-title":"BMC Med Ethics"},{"key":"5204_CR85","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/sctm.17-0282","volume":"7","author":"G Bauer","year":"2018","unstructured":"Bauer G, Elsallab M, Abou-El-Enein M, Standards. Protocols, policies, and regulations for cell-based therapies. Stem Cells Translational Med. 2018;7:676\u201385.","journal-title":"Stem Cells Translational Med"},{"key":"5204_CR86","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.stem.2012.05.010","volume":"10","author":"GQ Daley","year":"2012","unstructured":"Daley GQ. The promise and perils of stem cell therapeutics. Cell Stem Cell. 2012;10:740\u20139.","journal-title":"Cell Stem Cell"},{"key":"5204_CR87","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.stem.2015.06.007","volume":"17","author":"A Trounson","year":"2015","unstructured":"Trounson A, McDonald C. Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell. 2015;17:11\u201322.","journal-title":"Cell Stem Cell"},{"key":"5204_CR88","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1007\/s00018-020-03454-6","volume":"77","author":"X-L Fan","year":"2020","unstructured":"Fan X-L, Zhang Y, Li X, Fu Q-L. Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy. Cell Mol Life Sci. 2020;77:2771\u201394.","journal-title":"Cell Mol Life Sci"},{"key":"5204_CR89","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1080\/17460751.2025.2580888","volume":"20","author":"P Musyuni","year":"2025","unstructured":"Musyuni P, Mangla B, Javed S, Kumar P, Ahsan W. Regulatory challenges and opportunities in cell-based therapies: overcoming barriers to advancement and patient care. Regen Med. 2025;20:609\u201324.","journal-title":"Regen Med"},{"key":"5204_CR90","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMp1613723","volume":"376","author":"PW Marks","year":"2017","unstructured":"Marks PW, Witten CM, Califf RM. Clarifying stem-cell therapy\u2019s benefits and risks. N Engl J Med. 2017;376:1008\u20139.","journal-title":"N Engl J Med"},{"key":"5204_CR91","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/j.jcyt.2014.08.007","volume":"16","author":"N Cuende","year":"2014","unstructured":"Cuende N, et al. The puzzling situation of hospital exemption for advanced therapy medicinal products in Europe and stakeholders\u2019 concerns. Cytotherapy. 2014;16:1597\u2013600.","journal-title":"Cytotherapy"},{"key":"5204_CR92","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMp1613723","volume":"376","author":"PW Marks","year":"2017","unstructured":"Marks PW, Witten CM, Califf RM. Clarifying stem-cell therapy\u2019s benefits and risks. N Engl J Med. 2017;376:1008\u20139.","journal-title":"N Engl J Med"},{"key":"5204_CR93","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.stem.2012.05.010","volume":"10","author":"GQ Daley","year":"2012","unstructured":"Daley GQ. The promise and perils of stem cell therapeutics. Cell Stem Cell. 2012;10:740\u20139.","journal-title":"Cell Stem Cell"},{"key":"5204_CR94","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul H, et al. CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. N Engl J Med. 2021;384:252\u201360.","journal-title":"N Engl J Med"},{"key":"5204_CR95","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1182\/blood-2023-190139","volume":"142","author":"H Frangoul","year":"2023","unstructured":"Frangoul H, et al. Exagamglogene autotemcel for severe sickle cell disease. Blood. 2023;142:1052.","journal-title":"Blood"},{"key":"5204_CR96","doi-asserted-by":"crossref","unstructured":"Esrick EB, Bauer DE. Genetic therapies for sickle cell disease. Volume 55. Elsevier; 2018;76\u201386.","DOI":"10.1053\/j.seminhematol.2018.04.014"},{"key":"5204_CR97","doi-asserted-by":"publisher","first-page":"6618","DOI":"10.1097\/MS9.0000000000003823","volume":"87","author":"EI Obeagu","year":"2025","unstructured":"Obeagu EI. Umbilical cord blood: a comprehensive review of protective and restorative properties in clinical applications\u2013a narrative review. Annals Med Surg. 2025;87:6618\u201325.","journal-title":"Annals Med Surg"},{"key":"5204_CR98","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1080\/17460441.2023.2234280","volume":"18","author":"AC Juraski","year":"2023","unstructured":"Juraski AC, et al. 3D bioprinting for organ and organoid models and disease modeling. Expert Opin Drug Discov. 2023;18:1043\u201359.","journal-title":"Expert Opin Drug Discov"},{"key":"5204_CR99","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12887-021-02562-x","volume":"21","author":"Y Lan","year":"2021","unstructured":"Lan Y, et al. Combination of umbilical cord mesenchymal stem cells and standard immunosuppressive regimen for pediatric patients with severe aplastic anemia. BMC Pediatr. 2021;21:102.","journal-title":"BMC Pediatr"},{"key":"5204_CR100","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s13287-022-03112-7","volume":"13","author":"W Morello","year":"2022","unstructured":"Morello W, et al. First clinical application of cord blood mesenchymal stromal cells in children with multi-drug resistant nephrotic syndrome. Stem Cell Res Ther. 2022;13:420.","journal-title":"Stem Cell Res Ther"},{"key":"5204_CR101","unstructured":"Roura CD et al. Opportunities and Challenges with CAR T-cell Treatment of Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: Review and Recommendations from the Westhafen Intercontinental Group. Transplantation Cell Therapy. 2025."},{"key":"5204_CR102","first-page":"901","volume":"10","author":"H Dong","year":"2018","unstructured":"Dong H, et al. Umbilical cord mesenchymal stem cell (UC-MSC) transplantations for cerebral palsy. Am J Translational Res. 2018;10:901.","journal-title":"Am J Translational Res"},{"key":"5204_CR103","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1126\/science.282.5391.1145","volume":"282","author":"JA Thomson","year":"1998","unstructured":"Thomson JA, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282:1145\u20137.","journal-title":"Science"},{"key":"5204_CR104","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1002\/sctm.17-0051","volume":"6","author":"AI Caplan","year":"2017","unstructured":"Caplan AI. Mesenchymal stem cells: time to change the name! Stem cells translational Med. 2017;6:1445\u201351.","journal-title":"Stem cells translational Med"},{"key":"5204_CR105","doi-asserted-by":"crossref","unstructured":"Weissman IL. Stem cells: units of development, units of regeneration, and units in evolution. Cell 2000;100:157\u2013168.","DOI":"10.1016\/S0092-8674(00)81692-X"},{"key":"5204_CR106","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.stemcr.2021.05.012","volume":"16","author":"R Lovell-Badge","year":"2021","unstructured":"Lovell-Badge R, et al. ISSCR guidelines for stem cell research and clinical translation: the 2021 update. Stem cell Rep. 2021;16:1398\u2013408.","journal-title":"Stem cell Rep"},{"key":"5204_CR107","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2014.0376","author":"GQ Daley","year":"2015","unstructured":"Daley GQ. Stem cells and the evolving notion of cellular identity. Philos Trans R Soc Lond B Biol Sci. 2015. https:\/\/doi.org\/10.1098\/rstb.2014.0376.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"5204_CR108","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861\u201372.","journal-title":"Cell"},{"key":"5204_CR109","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"K Takahashi","year":"2006","unstructured":"Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663\u201376.","journal-title":"Cell"},{"key":"5204_CR110","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/bs.pbr.2017.02.008","volume":"230","author":"L Studer","year":"2017","unstructured":"Studer L. Strategies for bringing stem cell-derived dopamine neurons to the clinic\u2014the NYSTEM trial. Prog Brain Res. 2017;230:191\u2013212.","journal-title":"Prog Brain Res"},{"key":"5204_CR111","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/nbt1119","volume":"23","author":"S Goldman","year":"2005","unstructured":"Goldman S. Stem and progenitor cell\u2013based therapy of the human central nervous system. Nat Biotechnol. 2005;23:862\u201371.","journal-title":"Nat Biotechnol"},{"key":"5204_CR112","doi-asserted-by":"publisher","first-page":"R32","DOI":"10.1093\/hmg\/ddt379","volume":"22","author":"CN Svendsen","year":"2013","unstructured":"Svendsen CN. Back to the future: how human induced pluripotent stem cells will transform regenerative medicine. Hum Mol Genet. 2013;22:R32\u20138.","journal-title":"Hum Mol Genet"},{"key":"5204_CR113","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2307\/3570877","volume":"13","author":"EA McCulloch","year":"1960","unstructured":"McCulloch EA, Till JE. The radiation sensitivity of normal mouse bone marrow cells, determined by quantitative marrow transplantation into irradiated mice. Radiat Res. 1960;13:115\u201325.","journal-title":"Radiat Res"},{"key":"5204_CR114","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1056\/NEJMp078166","volume":"357","author":"FR Appelbaum","year":"2007","unstructured":"Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med. 2007;357:1472\u20135.","journal-title":"N Engl J Med"},{"key":"5204_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1146835","volume":"11","author":"A-H Soliman","year":"2023","unstructured":"Soliman A-H, Abdellatif M. COVID-19 disease treatment: pivotal challenges in the arena of umbilical cord-mesenchymal stem cells (UC-MSCs). Front Cell Dev Biol. 2023;11:1146835.","journal-title":"Front Cell Dev Biol"},{"key":"5204_CR116","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/mt.2009.62","volume":"17","author":"DJ Prockop","year":"2009","unstructured":"Prockop DJ. Repair of tissues by adult stem\/progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol Ther. 2009;17:939\u201346.","journal-title":"Mol Ther"},{"key":"5204_CR117","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1001\/jama.2015.1492","volume":"313","author":"A Atala","year":"2015","unstructured":"Atala A, Murphy S. Regenerative medicine. JAMA. 2015;313:1413\u20134.","journal-title":"JAMA"},{"key":"5204_CR118","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0896-6273(04)00111-4","volume":"41","author":"A Alvarez-Buylla","year":"2004","unstructured":"Alvarez-Buylla A, Lim DA. For the long run: maintaining germinal niches in the adult brain. Neuron. 2004;41:683\u20136.","journal-title":"Neuron"},{"key":"5204_CR119","doi-asserted-by":"publisher","first-page":"7599","DOI":"10.1523\/JNEUROSCI.16-23-07599.1996","volume":"16","author":"S Weiss","year":"1996","unstructured":"Weiss S, et al. Multipotent CNS stem cells are present in the adult mammalian spinal cord and ventricular neuroaxis. J Neurosci. 1996;16:7599\u2013609.","journal-title":"J Neurosci"},{"key":"5204_CR120","doi-asserted-by":"crossref","unstructured":"Okano H, et al. Transplantation of neural stem cells into the spinal cord after injury. Volume 14. Elsevier; 2003:191\u20138.","DOI":"10.1016\/S1084-9521(03)00011-9"},{"key":"5204_CR121","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1210\/er.2003-0027","volume":"25","author":"N Ferrara","year":"2004","unstructured":"Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581\u2013611.","journal-title":"Endocr Rev"},{"key":"5204_CR122","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1101\/gad.1303605","volume":"19","author":"G Keller","year":"2005","unstructured":"Keller G. Embryonic stem cell differentiation: emergence of a new era in biology and medicine. Genes Dev. 2005;19:1129\u201355.","journal-title":"Genes Dev"},{"key":"5204_CR123","doi-asserted-by":"publisher","first-page":"1F","DOI":"10.1002\/9780470151808.sc01f10s14","volume":"14","author":"X Huang","year":"2010","unstructured":"Huang X, Wu SM. Isolation and functional characterization of pluripotent stem cell\u2013derived cardiac progenitor cells. Curr Protoc Stem Cell Biol. 2010;14:1F \u2013 10.","journal-title":"Curr Protoc Stem Cell Biol"},{"key":"5204_CR124","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.cell.2008.02.008","volume":"132","author":"CE Murry","year":"2008","unstructured":"Murry CE, Keller G. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell. 2008;132:661\u201380.","journal-title":"Cell"},{"key":"5204_CR125","doi-asserted-by":"publisher","first-page":"a007864","DOI":"10.1101\/cshperspect.a007864","volume":"4","author":"K Willert","year":"2012","unstructured":"Willert K, Nusse R. Wnt proteins. Cold Spring Harb Perspect Biol. 2012;4:a007864.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"5204_CR126","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1161\/CIRCRESAHA.110.227512","volume":"111","author":"CL Mummery","year":"2012","unstructured":"Mummery CL, et al. Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circ Res. 2012;111:344\u201358.","journal-title":"Circ Res"},{"key":"5204_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2022.101149","volume":"43","author":"T Almas","year":"2022","unstructured":"Almas T, et al. Nanotechnology in interventional cardiology: a state-of-the-art review. IJC Heart Vasculature. 2022;43:101149.","journal-title":"IJC Heart Vasculature"},{"key":"5204_CR128","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13287-025-04334-1","volume":"16","author":"HE Marei","year":"2025","unstructured":"Marei HE. Stem cell therapy: a revolutionary cure or a pandora\u2019s box. Stem Cell Res Ther. 2025;16:255.","journal-title":"Stem Cell Res Ther"},{"key":"5204_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.gpeds.2024.100196","volume":"9","author":"V Gallo","year":"2024","unstructured":"Gallo V, Aiuti A. Gene therapy for rare haematological and neurometabolic paediatric diseases. Glob Pediatr. 2024;9:100196.","journal-title":"Glob Pediatr"},{"key":"5204_CR130","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2025.1663600","volume":"13","author":"L Hiskey","year":"2025","unstructured":"Hiskey L, Hijano DR, Zakhour R. Revisiting cytomegalovirus in pediatric allogeneic hematopoietic stem cell transplant recipients: current strategies for prevention and management in the letermovir era. Front Pediatr. 2025;13:1663600.","journal-title":"Front Pediatr"},{"key":"5204_CR131","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.ymthe.2024.03.005","volume":"32","author":"F Locatelli","year":"2024","unstructured":"Locatelli F, et al. Autologous gene therapy for hemoglobinopathies: From bench to patient\u2019s bedside. Mol Ther. 2024;32:1202\u201318.","journal-title":"Mol Ther"},{"key":"5204_CR132","first-page":"45","volume":"128","author":"MP Cicalese","year":"2016","unstructured":"Cicalese MP, et al. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. Blood J Am Soc Hematol. 2016;128:45\u201354.","journal-title":"Blood J Am Soc Hematol"},{"key":"5204_CR133","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul H, et al. CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. N Engl J Med. 2021;384:252\u201360.","journal-title":"N Engl J Med"},{"key":"5204_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-025-04550-9","volume":"16","author":"R Fatahi","year":"2025","unstructured":"Fatahi R, Heydarpour F, Motlagh SM, Mansouri K. Evaluation of stem\/stromal cell transplantation safety and efficacy in children diagnosed with cerebral palsy: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Ther. 2025;16:468.","journal-title":"Stem Cell Res Ther"},{"key":"5204_CR135","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.567210","volume":"11","author":"O Ringd\u00e9n","year":"2020","unstructured":"Ringd\u00e9n O, Gustafsson B, Sadeghi B. Mesenchymal stromal cells in pediatric hematopoietic cell transplantation a review and a pilot study in children treated with decidua stromal cells for acute graft-versus-host disease. Front Immunol. 2020;11:567210.","journal-title":"Front Immunol"},{"key":"5204_CR136","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41409-019-0546-9","volume":"55","author":"H Mayani","year":"2020","unstructured":"Mayani H, Wagner JE, Broxmeyer HE. Cord blood research, banking, and transplantation: achievements, challenges, and perspectives. Bone Marrow Transplant. 2020;55:48\u201361.","journal-title":"Bone Marrow Transplant"},{"key":"5204_CR137","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1089\/ten.tea.2020.0088","volume":"27","author":"D Iacobazzi","year":"2021","unstructured":"Iacobazzi D, et al. Wharton\u2019s jelly-mesenchymal stem cell-engineered conduit for pediatric translation in heart defect. Tissue Eng Part A. 2021;27:201\u201313.","journal-title":"Tissue Eng Part A"},{"key":"5204_CR138","doi-asserted-by":"publisher","DOI":"10.1093\/stcltm\/szaf050","volume":"14","author":"S Hwang","year":"2025","unstructured":"Hwang S, et al. Extracellular vesicles from mesenchymal stromal cells: an emerging therapy for intractable neonatal disorders. Stem Cells Transl Med. 2025;14:szaf050.","journal-title":"Stem Cells Transl Med"},{"key":"5204_CR139","doi-asserted-by":"publisher","first-page":"5979","DOI":"10.7150\/thno.40122","volume":"10","author":"S Varderidou-Minasian","year":"2020","unstructured":"Varderidou-Minasian S, Lorenowicz MJ. Mesenchymal stromal\/stem cell-derived extracellular vesicles in tissue repair: challenges and opportunities. Theranostics. 2020;10:5979.","journal-title":"Theranostics"},{"key":"5204_CR140","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1089\/scd.2020.0191","volume":"30","author":"M D\u00f6ring","year":"2021","unstructured":"D\u00f6ring M, et al. Long-term follow-up after the application of mesenchymal stromal cells in children and adolescents with steroid-refractory graft-versus-host disease. Stem Cells Dev. 2021;30:234\u201346.","journal-title":"Stem Cells Dev"},{"key":"5204_CR141","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.bbmt.2020.01.018","volume":"26","author":"J Kurtzberg","year":"2020","unstructured":"Kurtzberg J, et al. A phase 3, single-arm, prospective study of remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant. 2020;26:845\u201354.","journal-title":"Biol Blood Marrow Transplant"},{"key":"5204_CR142","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1002\/sctm.17-0102","volume":"6","author":"JM Sun","year":"2017","unstructured":"Sun JM, et al. Effect of autologous cord blood infusion on motor function and brain connectivity in young children with cerebral palsy: a randomized, placebo-controlled trial. Stem Cells Transl Med. 2017;6:2071\u20138.","journal-title":"Stem Cells Transl Med"},{"key":"5204_CR143","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.5966\/sctm.2015-0372","volume":"5","author":"I Novak","year":"2016","unstructured":"Novak I, et al. Concise review: stem cell interventions for people with cerebral palsy: systematic review with meta-analysis. Stem Cells Transl Med. 2016;5:1014\u201325.","journal-title":"Stem Cells Transl Med"},{"key":"5204_CR144","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/stcltm\/szad027","volume":"12","author":"CM Cotten","year":"2023","unstructured":"Cotten CM, et al. A pilot phase I trial of allogeneic umbilical cord tissue-derived mesenchymal stromal cells in neonates with hypoxic-ischemic encephalopathy. Stem Cells Transl Med. 2023;12:355\u201364.","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"5204_CR145","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1038\/s41598-020-61311-9","volume":"10","author":"M Tsuji","year":"2020","unstructured":"Tsuji M, et al. Autologous cord blood cell therapy for neonatal hypoxic-ischaemic encephalopathy: a pilot study for feasibility and safety. Sci Rep. 2020;10:4603.","journal-title":"Sci Rep"},{"key":"5204_CR146","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3390\/jpm13081281","volume":"13","author":"F Huang","year":"2023","unstructured":"Huang F, et al. Progress in research on stem cells in neonatal refractory diseases. J Personalized Med. 2023;13:1281.","journal-title":"J Personalized Med"},{"key":"5204_CR147","first-page":"1428","volume":"129","author":"A Bacigalupo","year":"2017","unstructured":"Bacigalupo A. How I treat acquired aplastic anemia. Blood J Am Soc Hematol. 2017;129:1428\u201336.","journal-title":"Blood J Am Soc Hematol"},{"key":"5204_CR148","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","volume":"33","author":"C-H Pui","year":"2015","unstructured":"Pui C-H, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33:2938\u201348.","journal-title":"J Clin Oncol"},{"key":"5204_CR149","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1089\/hum.2021.053","volume":"32","author":"P Bougneres","year":"2021","unstructured":"Bougneres P, et al. Long-term follow-up of hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. Hum Gene Ther. 2021;32:1260\u20139.","journal-title":"Hum Gene Ther"},{"key":"5204_CR150","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1126\/science.1171242","volume":"326","author":"N Cartier","year":"2009","unstructured":"Cartier N, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 2009;326:818\u201323.","journal-title":"Science"},{"key":"5204_CR151","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","volume":"399","author":"F Fumagalli","year":"2022","unstructured":"Fumagalli F, et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access. Lancet (London, England). 2022;399:372\u201383.","journal-title":"Lancet (London, England)"},{"key":"5204_CR152","first-page":"45","volume":"128","author":"MP Cicalese","year":"2016","unstructured":"Cicalese MP, et al. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. Blood J Am Soc Hematol. 2016;128:45\u201354.","journal-title":"Blood J Am Soc Hematol"},{"key":"5204_CR153","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41591-019-0735-5","volume":"26","author":"DB Kohn","year":"2020","unstructured":"Kohn DB, et al. Lentiviral gene therapy for X-linked chronic granulomatous disease. Nat Med. 2020;26:200\u20136.","journal-title":"Nat Med"},{"key":"5204_CR154","unstructured":"Cyr-Depauw C. Defining the Next-Generation Umbilical Cord-Derived Cell Therapy for Treatment of Bronchopulmonary Dysplasia. 2023."},{"key":"5204_CR155","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1007\/s00018-020-03454-6","volume":"77","author":"X-L Fan","year":"2020","unstructured":"Fan X-L, Zhang Y, Li X, Fu Q-L. Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy. Cell Mol Life Sci. 2020;77:2771\u201394.","journal-title":"Cell Mol Life Sci"},{"key":"5204_CR156","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41587-019-0016-3","volume":"37","author":"T Deuse","year":"2019","unstructured":"Deuse T, et al. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. Nat Biotechnol. 2019;37:252\u20138.","journal-title":"Nat Biotechnol"},{"key":"5204_CR157","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","volume":"22","author":"J Galipeau","year":"2018","unstructured":"Galipeau J, Sens\u00e9b\u00e9 L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22:824\u201333.","journal-title":"Cell Stem Cell"},{"key":"5204_CR158","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jcyt.2015.11.008","volume":"18","author":"J Galipeau","year":"2016","unstructured":"Galipeau J, et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. 2016;18:151\u20139.","journal-title":"Cytotherapy"},{"key":"5204_CR159","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.1007\/s12010-023-04752-y","volume":"196","author":"W Chen","year":"2024","unstructured":"Chen W, Ren Q, Zhou J, Liu W. Mesenchymal stem cell-induced neuroprotection in pediatric neurological diseases: Recent update of underlying mechanisms and clinical utility. Appl Biochem Biotechnol. 2024;196:5843\u201358.","journal-title":"Appl Biochem Biotechnol"},{"key":"5204_CR160","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s13287-022-02973-2","volume":"13","author":"Y Ji","year":"2022","unstructured":"Ji Y, et al. Clinical trials of stem cell-based therapies for pediatric diseases: a comprehensive analysis of trials registered on ClinicalTrials. gov and the ICTRP portal site. Stem Cell Res Ther. 2022;13:307.","journal-title":"Stem Cell Res Ther"},{"key":"5204_CR161","doi-asserted-by":"publisher","first-page":"539","DOI":"10.5966\/sctm.2015-0427","volume":"6","author":"CR Nitkin","year":"2017","unstructured":"Nitkin CR, Bonfield TL. Concise review: mesenchymal stem cell therapy for pediatric disease: perspectives on success and potential improvements. Stem cells translational Med. 2017;6:539\u201365.","journal-title":"Stem cells translational Med"},{"key":"5204_CR162","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/nbt.3084","volume":"32","author":"M Abou-El-Enein","year":"2014","unstructured":"Abou-El-Enein M, Bauer G, Reinke P. The business case for cell and gene therapies. Nat Biotechnol. 2014;32:1192\u20133.","journal-title":"Nat Biotechnol"},{"key":"5204_CR163","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.jcyt.2017.07.005","volume":"19","author":"RP Harrison","year":"2017","unstructured":"Harrison RP, Ruck S, Medcalf N, Rafiq QA. Decentralized manufacturing of cell and gene therapies: overcoming challenges and identifying opportunities. Cytotherapy. 2017;19:1140\u201351.","journal-title":"Cytotherapy"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-026-05204-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05204-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05204-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:01:58Z","timestamp":1787104918000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13287-026-05204-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,15]]},"references-count":163,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5204"],"URL":"https:\/\/doi.org\/10.1186\/s13287-026-05204-0","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,15]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not Applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This review article does not contain any studies involving human participants or animals performed by the author, nor does it include any identifiable personal data.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"287"}}